Lifeloc Technologies, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, reporting a net loss of $84,931 for the third quarter, a narrowing from the $263,439 net loss recorded in the same quarter of the prior year.

Key Highlights

  • Q3 2026 net loss: $84,931, compared with a net loss of $263,439 in Q3 2025, according to the filing.
  • Q3 2026 total revenue: $2,521,874, up from $2,257,448 in Q3 2025, driven primarily by product sales of $2,512,530.
  • Nine-month net loss: $371,974 for the nine months ended September 30, 2026, compared with $949,764 for the same period in 2025.
  • Total assets: $7,002,628 as of September 30, 2026, up from $6,686,568 at December 31, 2025.
  • Accumulated deficit: $2,202,510 as of September 30, 2026, compared with $1,830,536 at December 31, 2025.
  • New related-party debt: A term loan payable to a related party appeared on the balance sheet, with a current portion of $59,396 and a non-current portion of $440,604, totaling $500,000.
  • Shares outstanding: 2,752,616 shares of common stock as of October 31, 2026.

Lifeloc Technologies Reports Narrower Loss and Higher Revenue in Q3 2026

According to the filing, Lifeloc Technologies reported total revenues of $2,521,874 for the three months ended September 30, 2026, compared with $2,257,448 for the same period in 2025. Product sales accounted for $2,512,530 of that total, with royalties contributing $9,344. Gross profit for the quarter was $1,090,082, up from $906,693 in Q3 2025. Total operating expenses were $1,140,153, resulting in an operating loss of $50,071 for the quarter, compared with an operating loss of $234,326 in Q3 2025.

For the nine months ended September 30, 2026, the company disclosed total revenues of $7,260,643, up from $6,753,858 in the comparable 2025 period. Nine-month gross profit was $3,169,682 versus $2,739,858 a year earlier. Operating expenses for the nine-month period totaled $3,451,331, down from $3,632,997 in the prior-year period. The resulting nine-month operating loss was $281,649, compared with $893,139 for the nine months ended September 30, 2025, according to the filing.

On the balance sheet, the company reported cash and cash equivalents of $930,539 as of September 30, 2026, up from $746,001 at December 31, 2025. Total liabilities rose to $3,270,824 from $2,582,790 at year-end 2025, with the increase attributable in part to new related-party term loan balances totaling $500,000 (current and non-current portions combined) that were not present at December 31, 2025. Total stockholders' equity was $3,731,804 as of September 30, 2026, down from $4,103,778 at December 31, 2025. The company is classified as a non-accelerated filer and a smaller reporting company, with no securities registered under Section 12(b) of the Act.

What Was Disclosed

Lifeloc Technologies filed its unaudited quarterly report covering the period ended September 30, 2026, disclosing a narrowed quarterly net loss, higher product sales revenue compared with the prior year, a new related-party term loan, and an accumulated deficit of $2,202,510.